Follow DNDi on LinkedInFollow DNDi on TwitterFollow DNDi on Facebook

Over 1 billion people, including 500 million children, in the poorest regions of the world, are affected by neglected diseases that debilitate, disfigure or kill.

DNDi’s research and development approach is driven by the real day-to-day needs of patients and healthcare providers.

By connecting public and private partners, DNDi synergizes expertise and capitalizes upon the best science. 

DNDi also works to strengthen the health R&D field in the countries where the diseases occur in order to reinforce capacities for sustainable change.

Major progress has been made with six new treatments made available since the creation of DNDi, in 2003. However, major breakthroughs are still needed to treat neglected patients: Entirely new, affordable, and adapted drugs will change the lives of millions of people.



Read DNDi's 2013 Annual Report: "A Decade of R&D for Neglected Patients" More

In pictures: filaria in Ghana

Filarial diseases devastate the lives of patients, causing debilitating symptoms and social discrimination. DNDi traveled to rural Ghana to meet and interview patients with filaria and the physician-researchers treating them. More

Pilot Pooled Fund for R&D

This recent paper commissioned by DNDi examines the possibilities of creating a pooled international R&D fund for the Demonstration Projects selected as part of the process following on the report of the WHO Consultative Expert Working Group on R&D (CEWG). More


Fexinidazole: launch of Phase II/III clinical trial in the Democratic Republic of Congo and Central African Republic.The study, initiated by DNDi and its partners, will test the efficacy and safety of fexinidazole, with once daily tablets for ten days. More


Testimonies of South African mothers: demonstrating the difficulties in administering current treatments for paediatric HIV More


Voices for neglected diseases. Lemarus Tebakwani Lukeno has been treated with SSG&PM for kala-azar; read his and other patient stories More


320 million treatments of ASAQ, DNDi and Sanofi’s antimalarial combination therapy of Artesunate and Amodiaquine, have been distributed in over 30 countries since its launch in 2007! More



March 17-18, 2015
GLOBVAC Conference 2015
Oslo, Norway
DNDi will be participating in a symposium on sleeping sickness.

May 20-21, 2015
ISNTD d3 2015
London, United Kingdom
DNDi will be presenting on drug discovery for leishmaniasis and Chagas disease.

See all events



DNDi Model Paper
DNDi has issued a report that explores the lessons learned from a decade of R&D of new treatments for neglected diseases via a cost-effective, innovative, not-for-profit drug development model. Read more


Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site
is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License